Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBI-d: Dabrafenib + Trametinib in BRAF V600E/K Mutation-Positive Melanoma
NCT01584648Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2012
- Primary completion
- Aug 2013
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of trametinib in cutaneous melanoma (CM), sponsored by Novartis. Started May 2012; status: completed.
02
Drugs
trametinib
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT01584648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01584648.